论文部分内容阅读
目的探讨阿昔洛韦联合病毒唑在治疗手足口病中的作用。方法以我院2010年1月～2013年1月间收治的80例手足口病患儿为研究对象,随机分为观察组与对照组,观察组患者联合使用阿昔洛韦和病毒唑,对照组患者只是用病毒唑。比较两组患者临床疗效和临床症状改善情况。结果观察组患者临床疗效显效率高于对照组,临床症状改善时间少于对照组,其差异皆有统计学意义(P<0.05)。结论联合使用阿昔洛韦和病毒唑,可以有效提高手足口病患者的临床疗效,并快速改善患者临床症状。
Objective To investigate the role of acyclovir and ribavirin in the treatment of hand-foot-mouth disease. Methods Eighty children with HFMD treated in our hospital from January 2010 to January 2013 were randomly divided into the observation group and the control group. The patients in the observation group were treated with acyclovir and ribavirin. The control group Group patients just use ribavirin. The clinical efficacy and clinical symptom improvement were compared between the two groups. Results The effective rate of clinical curative effect in the observation group was higher than that of the control group, and the improvement time of clinical symptoms was less than that of the control group. The difference was statistically significant (P <0.05). Conclusion The combination of acyclovir and ribavirin can effectively improve the clinical efficacy of HFMD patients and rapidly improve the clinical symptoms.